留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肺大细胞神经内分泌癌的诊断及治疗

陈野野 刘洪生 李单青

陈野野, 刘洪生, 李单青. 肺大细胞神经内分泌癌的诊断及治疗[J]. 协和医学杂志, 2019, 10(4): 393-397. doi: 10.3969/j.issn.1674-9081.2019.04.016
引用本文: 陈野野, 刘洪生, 李单青. 肺大细胞神经内分泌癌的诊断及治疗[J]. 协和医学杂志, 2019, 10(4): 393-397. doi: 10.3969/j.issn.1674-9081.2019.04.016
Ye-ye CHEN, Hong-sheng LIU, Shan-qing LI. Diagnosis and Treatment of Pulmonary Large-cell Neuroendocrine Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(4): 393-397. doi: 10.3969/j.issn.1674-9081.2019.04.016
Citation: Ye-ye CHEN, Hong-sheng LIU, Shan-qing LI. Diagnosis and Treatment of Pulmonary Large-cell Neuroendocrine Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(4): 393-397. doi: 10.3969/j.issn.1674-9081.2019.04.016

肺大细胞神经内分泌癌的诊断及治疗

doi: 10.3969/j.issn.1674-9081.2019.04.016
详细信息
    通讯作者:

    李单青电话:010-69152630,E-mail:pumchlsq@163.com

  • 中图分类号: R734.1

Diagnosis and Treatment of Pulmonary Large-cell Neuroendocrine Carcinoma

More Information
    Corresponding author: LI Shan-qing Tel: 86-10-69152630, E-mail: pumchlsq@163.com
  • 摘要: 肺大细胞神经内分泌癌(pulmonary large-cell neuroendocrine carcinoma,LCNEC)是一种罕见的肺部上皮性恶性肿瘤,1991年被首次报道,2004年病理分型正式划归支气管肺神经内分泌肿瘤。该病多见于高龄吸烟男性,临床表现无特异性,可有呼吸道相关症状,副肿瘤综合征罕见,CT常表现为外周型结节影,可有分叶、毛刺及胸膜牵拉。LCNEC恶性程度高,患者诊断时约60%~80%出现淋巴结转移,40%出现远处转移,恶性程度接近小细胞肺癌。手术联合术后辅助治疗是Ⅰ、Ⅱ、Ⅲa期患者的主要治疗手段,化疗建议PE方案(顺铂联合依托泊苷)。转移及术后复发可能是预后不良的主要原因,肿瘤驱动基因及进一步靶向药物治疗尚有待进一步研究。
    利益冲突  无
  • [1] Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States[J]. J Clin Oncol, 2008, 26:3063-3072. doi:  10.1200/JCO.2007.15.4377
    [2] Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors[J]. Cancer, 2008, 113:5-21. doi:  10.1002/cncr.23542
    [3] Sanchez de Cos Escuin J. Diagnosis and treatment of neuroendocrine lung tumors[J]. Arch Bronconeumol, 2014, 50:392-396. http://www.ncbi.nlm.nih.gov/pubmed/24685201
    [4] Travis WD, Brambilla E, Burke AP, et al.Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart[J]. J Thorac Oncol, 2015, 10:1240-1242. doi:  10.1097/JTO.0000000000000663
    [5] Jiang SX, Kameya T, Shoji M, et al. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases[J]. Am J Surg Pathol, 1998, 22:526-537. doi:  10.1097/00000478-199805000-00002
    [6] Travis WD. Lung tumours with neuroendocrine differentiation[J]. Eur J Cancer, 2009, 45:251-266. doi:  10.1016/S0959-8049(09)70040-1
    [7] Detterbeck FC. Clinical presentation and evaluation of neuroendocrine tumors of the lung[J]. Thorac Surg Clin, 2014, 24:267-276. doi:  10.1016/j.thorsurg.2014.04.002
    [8] 陈野野, 李单青, 田震寰, 等.肺大细胞神经内分泌癌手术治疗及预后因素[J].协和医学杂志, 2016, 7:98-103. doi:  10.3969/j.issn.1674-9081.2016.02.004
    [9] Arrigoni MG, Woolner LB, Bernatz PE. Atypical carcinoid tumors of the lung[J]. J Thorac Cardiovasc Surg, 1972, 64:413-421. doi:  10.1016/S0022-5223(19)39836-8
    [10] Warren WH, Faber LP, Gould VE. Neuroendocrine neoplasms of the lung. A clinicopathologic update[J]. J Thorac Cardiovasc Surg, 1989, 98:321-332. doi:  10.1016/S0022-5223(19)34377-6
    [11] Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases[J]. Am J Surg Pathol, 1991, 15:529-553. doi:  10.1097/00000478-199106000-00003
    [12] Shimosato Y.Histological Typing of Lung and Pleural Tumors (3rd edition, 1999): Malignant epithelial tumors[J]. Nihon Rinsho, 2002, 60 Suppl 5:123-131. https://jcp.bmj.com/content/54/7/498
    [13] Travis WD, Brambitta E, Müller-Hermelink HK. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart (WHO Classification of Tumours)[M]. Lyon: IARC Press, 2004:145-247.
    [14] Fasano M, Della Corte CM, Papaccio F, et al. Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy[J]. J Thorac Oncol, 2015, 10:1133-1141. doi:  10.1097/JTO.0000000000000589
    [15] Sakurai H, Asamura H. Large-cell neuroendocrine carcinoma of the lung: surgical management[J]. Thorac Surg Clin, 2014, 24:305-311. doi:  10.1016/j.thorsurg.2014.05.001
    [16] Iyoda A, Hiroshima K, Nakatani Y, et al. Pulmonary large cell neuroendocrine carcinoma: its place in the spectrum of pulmonary carcinoma[J]. Ann Thorac Surg, 2007, 84:702-707. doi:  10.1016/j.athoracsur.2007.03.093
    [17] Lo Russo G, Pusceddu S, Proto C, et al. Treatment of lung large cell neuroendocrine carcinoma[J]. Tumour Biol, 2016, 37:7047-7057. doi:  10.1007/s13277-016-5003-4
    [18] Chen YY, Li SQ, Liu HS, et al. Ectopic adrenocorticotropic hormone syndrome caused by neuroendocrine tumors of the thymus: 30-year experience with 16 patients at a single institute in the People's Republic of China[J]. Onco Targets Ther, 2016, 9:2193-2201. https://www.dovepress.com/ectopic-adrenocorticotropic-hormone-syndrome-caused-by-neuroendocrine--peer-reviewed-article-OTT
    [19] Paci M, Cavazza A, Annessi V, et al. Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study[J]. Ann Thorac Surg, 2004, 77:1163-1167. doi:  10.1016/j.athoracsur.2003.09.070
    [20] Glisson BS, Moran CA. Large-cell neuroendocrine carcinoma: controversies in diagnosis and treatment[J]. J Natl Compr Canc Netw, 2011, 9:1122-1129. doi:  10.6004/jnccn.2011.0093
    [21] Lee KW, Lee Y, Oh SW, et al. Large cell neuroendocrine carcinoma of the lung: CT and FDG PET findings[J]. Eur J Radiol, 2015, 84:2332-2338. doi:  10.1016/j.ejrad.2015.07.033
    [22] Oshiro Y, Kusumoto M, Matsuno Y, et al. CT findings of surgically resected large cell neuroendocrine carcinoma of the lung in 38 patients[J]. AJR Am J Roentgenol, 2004, 182:87-91. doi:  10.2214/ajr.182.1.1820087
    [23] Akata S, Okada S, Maeda J, et al. Computed tomographic findings of large cell neuroendocrine carcinoma of the lung[J]. Clin Imaging, 2007, 31:379-384. doi:  10.1016/j.clinimag.2007.04.027
    [24] Shin AR, Shin BK, Choi JA, et al. Large cell neuroen-docrine carcinoma of the lung: radiologic and pathologic find-ings[J]. J Comput Assist Tomogr, 2000, 24:567-573. doi:  10.1097/00004728-200007000-00010
    [25] Chong S, Lee KS, Kim BT, et al. Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications[J]. AJR Am J Roentgenol, 2007, 188:1223-1231. doi:  10.2214/AJR.06.0503
    [26] Papotti M, Croce S, Bello M, et al. Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy[J]. Virchows Arch, 2001, 439:787-797. doi:  10.1007/s004280100494
    [27] Rodrigues M, Traub-Weidinger T, Li S, et al. Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours[J]. Eur J Nucl Med Mol Imaging, 2006, 33:532-540. doi:  10.1007/s00259-005-0020-3
    [28] Eichhorn F, Dienemann H, Muley T, et al. Predictors of survival after operation among patients with large cell neuroendocrine carcinoma of the lung[J]. Ann Thorac Surg, 2015, 99:983-989. doi:  10.1016/j.athoracsur.2014.10.015
    [29] Lababede O, Meziane M, Rice T. Seventh edition of the cancer staging manual and stage grouping of lung cancer: quick reference chart and diagrams[J]. Chest, 2011, 139:183-189. doi:  10.1378/chest.10-1099
    [30] Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification[J]. J Thorac Oncol, 2015, 10:1243-1260. doi:  10.1097/JTO.0000000000000630
    [31] Iyoda A, Hiroshima K, Moriya Y, et al. Pulmonary large cell neuroendocrine carcinoma demonstrates high prolifera-tive activity[J]. Ann Thorac Surg, 2004, 77:1891-1895. doi:  10.1016/j.athoracsur.2003.10.119
    [32] Naidoo J, Santos-Zabala ML, Iyriboz T, et al. Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes[J]. Clin lung cancer, 2016, 17:e121-e129. doi:  10.1016/j.cllc.2016.01.003
    [33] den Bakker MA, Willemsen S, Grunberg K, et al. Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability[J]. Histopathology, 2010, 56:356-363. doi:  10.1111/j.1365-2559.2010.03486.x
    [34] Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification[J]. Arch Pathol Lab Med, 2013, 137:668-684. doi:  10.5858/arpa.2012-0263-RA
    [35] Pelosi G, Rodriguez J, Viale G, et al.Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients[J]. Am J Surg Pathol, 2005, 29:179-187. doi:  10.1097/01.pas.0000149690.75462.29
    [36] 陈野野, 李单青, 秦应之, 等. 74例电视纵隔镜临床应用[J].协和医学杂志, 2014, 5:189-191. doi:  10.3969/j.issn.1674-9081.2014.02.013
    [37] Iyoda A, Makino T, Koezuka S, et al. Treatment options for patients with large cell neuroendocrine carcinoma of the lung[J]. Gen Thorac Cardiovasc Surg, 2014, 62:351-356. doi:  10.1007/s11748-014-0379-9
    [38] Iyoda A, Hiroshima K, Moriya Y, et al. Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma[J]. J Thorac Cardiovasc Surg, 2009, 138:446-453. doi:  10.1016/j.jtcvs.2008.12.037
    [39] Igawa S, Watanabe R, Ito I, et al. Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer[J]. Lung Cancer, 2010, 68:438-445. doi:  10.1016/j.lungcan.2009.07.003
    [40] Sun JM, Ahn MJ, Ahn JS, et al. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? [J].Lung Cancer, 2012, 77:365-370. doi:  10.1016/j.lungcan.2012.04.009
    [41] De Pas TM, Giovannini M, Manzotti M, et al. Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib[J]. J Clin Oncol, 2011, 29:e819-e822. doi:  10.1200/JCO.2011.36.2251
  • 加载中
计量
  • 文章访问数:  512
  • HTML全文浏览量:  59
  • PDF下载量:  353
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-04-07
  • 刊出日期:  2019-07-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!